No impact of dapagliflozin on short-term BP variability in diabetics: Study
Greece: The use of SGLT2 inhibitor dapagliflozin does not affect short-term blood pressure variability (BPV) in type 2 diabetes (T2D) patients, suggests a recent study in the American Journal of Hypertension.
Increased BPV is known to increase the risk of cardiovascular and all-cause mortality in T2D patients. Sodium-glucose-co-transporter-2 (SGLT-2) inhibitors decrease the incidence of death, cardiovascular events, and renal events in this population. This study by Pantelis Sarafidis, University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece, and colleagues aimed to evaluate the effect of dapagliflozin on short-term BPV in T2D patients.
For the purpose, the researchers performed a secondary analysis of a double-blind, randomized, placebo-controlled trial in 85 T2D patients. The subjects were randomized to receive oral dapagliflozin 10mg once daily or placebo for 12 weeks. The patients underwent 24-h ambulatory blood pressure (BP) monitoring with the Mobil-O-Graph NG device at baseline and study-end. With the use of validated formulae for the 24-h and the daytime and nighttime periods, the researchers calculated Standard-deviation (SD), weighted-SD (wSD), coefficient-of-variation (CV), average-real-variability (ARV) and variation-independent-of-mean (VIM).
Key findings of the study include:
- Dapagliflozin reduced 24-h brachial BP compared to placebo. From baseline to study-end 24-h brachial BPV indexes did not change with dapagliflozin (SBP-ARV: 11.51±3.45 vs 11.05±3.35; SBP-wSD: 13.59±3.60 vs 13.48±3.33) or placebo (SBP-ARV: 11.47±3.63 vs 11.05±3.00; SBP-wSD: 13.85±4.38 vs 13.97±3.87).
- Similarly, no significant changes in BPV indexes for daytime and nighttime were observed in any group.
- At study-end, no differences between the groups were observed for any BPV index.
- Deltas(Δ) of all indexes during follow-up were minimal and not different between-groups (SBP-wSD: dapagliflozin: -0.11±3.05 vs placebo: 0.12±4.20).
"This study is the first to evaluate the effects of an SGLT-2 inhibitor on short-term BPV in patients with T2DM, showing no effect on dapagliflozin on all BPV indexes studied," concluded the authors.
The study, "Dapagliflozin does not affect short-term blood pressure variability in patients with type-2 diabetes mellitus," is published in the American Journal of Hypertension.
DOI: https://academic.oup.com/ajh/advance-article-abstract/doi/10.1093/ajh/hpaa207/6024653
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd